
|Videos|May 8, 2020
Expanding Options for Treatment of CLL Using BTK Inhibitors
Author(s)Targeted Oncology
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
4
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
5































